Interactive clinical discussion on XPOVIO
Loading Map....
XPOVIO (selinexor): Now approved as early as 1st relapse in multiple myeloma
BY: Rajesh Behl, MD
Alta Bates Summit Comprehensive Cancer Center
RSVP:
https://www.karyopharmevents.com/8xS9F4
866-914-9069 / VDE_KaryopharmRSVP@veeva.com
602-770-6148 / drobson@karyopharm.com
KAR0001372 Please reference this number during registration.